Malin Corporation (MLC.IR) Stock Price

Malin Corporation Price

CLOSED
7.00
+0.00 (+0.00 %)
Market closed

Over the last 5 years Malin Corporation grew revenue by 12.4% annually, reaching 41.00 M EUR. Earnings per share have declined at 38.2% per year over the last 2 years. For Malin Corporation, the net margin of 213.9% is up versus -198.3% a few years ago. The consensus 12-month price target for Malin Corporation is 15.81 EUR, about 125.9% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 3% above its 52-week low.

Malin Corporation stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Malin Corporation over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Malin Corporation stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Malin Corporation's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Malin Corporation Stock Price History
DateMalin Corporation Price
9/23/20267.00 EUR
9/22/20267.00 EUR
9/21/20266.80 EUR
9/18/20266.80 EUR
9/16/20267.00 EUR
9/15/20267.00 EUR
9/14/20267.00 EUR
9/11/20267.00 EUR
9/10/20267.00 EUR
9/9/20267.00 EUR
9/8/20267.00 EUR
9/4/20267.00 EUR
9/3/20267.00 EUR
9/2/20267.00 EUR
9/1/20267.00 EUR
8/31/20267.00 EUR
8/28/20267.00 EUR
8/27/20267.00 EUR
8/26/20267.00 EUR
8/25/20267.00 EUR
8/21/20267.00 EUR
8/20/20267.00 EUR
8/19/20267.00 EUR
8/18/20267.00 EUR
8/17/20267.00 EUR
8/14/20267.00 EUR
8/13/20267.00 EUR
8/12/20266.95 EUR
8/11/20267.00 EUR
8/10/20267.00 EUR
Access this data via the Eulerpool API

Malin Corporation Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
34.90 M EUR
-3.40 M EUR
-5.40 M EUR
Jan 1, 2020
41.00 M EUR
94.20 M EUR
87.70 M EUR
Jan 1, 2021
0.00 EUR
-2.60 M EUR
37.80 M EUR
Jan 1, 2022
0.00 EUR
-700,000.00 EUR
12.90 M EUR
Jan 1, 2023
0.00 EUR
-3.90 M EUR
0.00 EUR
Jan 1, 2024
0.00 EUR
-2.50 M EUR
0.00 EUR
Jan 1, 2025 (e)
0.00 EUR
-3.03 M EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
-3.03 M EUR
-4.19 M EUR

Malin Corporation Income Statement, Balance Sheet, Cash Flow Statement

Last updated Sep 25, 2026, 4:20 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e2026e
22.0042.0041.0038.0034.0041.00––––––
–90.91-2.38-7.32-10.5320.59––––––
13.6426.1926.8310.5320.5924.39––––––
3.0011.0011.004.007.0010.0010.0010.0010.0010.0010.0010.00
-27.00-81.00-45.00-44.00-3.0094.00-2.00–-3.00-2.00-3.00-3.00
-122.73-192.86-109.76-115.79-8.82229.27––––––
-44.00-83.00-98.00-46.00-5.0087.0037.0012.00–––-4.00
–88.6418.07-53.06-89.13-1,840.00-57.47-67.57––––
39.4041.8045.7045.9049.0349.2344.7418.9718.9718.9718.9718.97
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Malin Corporation generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Malin Corporation retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Malin Corporation's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Malin Corporation has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Malin Corporation's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Malin Corporation stock margins

The Malin Corporation margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Malin Corporation. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Malin Corporation.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
21.49 %
-9.74 %
-15.47 %
Jan 1, 2020
24.88 %
229.76 %
213.90 %
Jan 1, 2021
24.88 %
- %
- %
Jan 1, 2022
24.88 %
- %
- %
Jan 1, 2023
24.88 %
- %
0.00 %
Jan 1, 2024
24.88 %
- %
0.00 %
Jan 1, 2025 (e)
24.88 %
- %
0.00 %
Jan 1, 2026 (e)
24.88 %
- %
- %

Malin Corporation Stock Revenue, EBIT, Earnings per Share

The Malin Corporation earnings per share therefore indicates how much revenue Malin Corporation has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
0.71 EUR
-0.07 EUR
-0.11 EUR
Jan 1, 2020
0.83 EUR
1.91 EUR
1.78 EUR
Jan 1, 2021
0.00 EUR
-0.06 EUR
0.84 EUR
Jan 1, 2022
0.00 EUR
-0.04 EUR
0.68 EUR
Jan 1, 2023
0.00 EUR
-0.21 EUR
0.00 EUR
Jan 1, 2024
0.00 EUR
-0.13 EUR
0.00 EUR
Jan 1, 2025 (e)
0.00 EUR
-0.16 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
-0.16 EUR
-0.12 EUR

Malin Corporation business model & stock analysis

Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development. Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization. The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics. Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy. Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections. Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes. The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise. Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market. Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives.

Malin Corporation SWOT Analysis

Strengths

Malin Corporation is a well-established company in its industry, with a strong track record of success and a solid customer base.

The company has a diverse range of high-quality products and services, offering a competitive advantage in the market.

Malin Corporation has a skilled and experienced workforce, enabling efficient operations and excellent customer service.

Weaknesses

One of the weaknesses of Malin Corporation is its heavy reliance on a few key customers, which poses a significant risk to the business if those relationships are disrupted.

The company may also face challenges in keeping up with rapidly evolving technology and industry trends.

Malin Corporation has relatively high operational costs, which can put pressure on profitability.

Opportunities

There are several potential opportunities for Malin Corporation to explore, such as expanding into new markets or introducing innovative products/services.

The company can also benefit from strategic partnerships or acquisitions to enhance its capabilities and market presence.

The growing demand for sustainable and environmentally-friendly solutions presents a chance for Malin Corporation to align its products with these trends.

Threats

Malin Corporation faces potential threats from intense competition in the market, which may impact its market share and pricing power.

Economic downturns or fluctuations can also pose risks to the company's profitability and financial stability.

Regulatory changes in the industry can impact Malin Corporation's operations and require adjustments to comply with new standards.

Malin Corporation Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Malin Corporation historical P/E ratio, EBIT multiple, and P/S ratio

Malin Corporation annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down Malin Corporation's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in Malin Corporation's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Malin Corporation's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Malin Corporation shares outstanding

The number of shares of Malin Corporation was 18.97 M in 2025. This indicates how many shares Malin Corporation is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
49.03 M Stocks
Jan 1, 2020
49.23 M Stocks
Jan 1, 2021
44.74 M Stocks
Jan 1, 2022
18.97 M Stocks
Jan 1, 2023
18.97 M Stocks
Jan 1, 2024
18.97 M Stocks
Jan 1, 2025 (e)
18.97 M Stocks
Jan 1, 2026 (e)
18.97 M Stocks

Current Malin Corporation forecasts and price targets in September 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
15.81
Last Price
7.00
Currency
EUR
12M Return Potential
125.86 %
LTM Return
-19.08 %

Malin Corporation shareholder structure

% Name
3.20398%
Pentwater Capital Management LP
Pentwater Capital Management LP
1.27080%
Reedy Creek Investments, LLC.
Reedy Creek Investments, LLC.
1.26872%
O'Driscol (Sean)
O'Driscol (Sean)
1.21004%
The Pension Protection Fund
The Pension Protection Fund
1.18146%
The National Treasury Management Agency
The National Treasury Management Agency
0.02548%
Dunlevy (Fiona)
Dunlevy (Fiona)

Malin Corporation Beneficial Ownership Filings (SEC 13D/G)

Free Float
47.4%
Float Shares
2.05 M
Shares Outstanding
4.33 M

Malin Corporation Executives and Management Board

12 members · avg. age 61 · 17 % women

Management

NM

Mr. Neil McLoughlin

General Counsel, Company Secretary

–
DD

David Dobrosky

Senior Analyst

–
PS

Mr. Peter Schwartzman

Member of Senior Management Team

–

Board of Directors

LD

Mr. Liam Daniel (63)

Non-Executive Chairman of the Board · since 2019

–
FD

Ms. Fiona Dunlevy

Executive Director

–
LC

Mr. Luke Corning (43)

Non-Executive Director

–
JC

Dr. Jean-Michel Cossery

Non-Executive Director

–
KD

Dr. Kirsten Drejer (69)

Non-Executive Director

–
OH

Mr. Owen Hughes (50)

Non-Executive Director

–

Frequently asked questions about Malin Corporation

The business model of Malin Corporation PLC is focused on strategic investments in life sciences companies with significant growth potential. Malin aims to provide capital, expertise, and operational support to enable these companies to reach their full potential and generate substantial returns. By investing in a diverse portfolio of innovative life sciences businesses, Malin seeks to create value for its shareholders and contribute to the advancement of breakthrough technologies and therapies. With an emphasis on long-term partnerships, Malin aims to drive sustainable growth in the life sciences sector by identifying and supporting promising companies in areas such as biotechnology, pharmaceuticals, and medical devices.

Malin Corporation PLC is primarily active in the industries of healthcare and life sciences.

The main competitors of Malin Corporation PLC in the market are [competitor names]. These competitors pose a challenge to Malin Corporation PLC by offering similar products and services [specific to the industry], thereby competing for market share. However, Malin Corporation PLC has positioned itself uniquely in the market by [highlighting key differentiators or strengths], giving it a competitive edge. Despite the competition, Malin Corporation PLC continues to strive for excellence through its innovative offerings and strategic initiatives in order to maintain and expand its market presence.

Malin Corporation PLC is an Irish-based global life sciences investment company. Founded in 2015, its primary focus is on creating long-term shareholder value through strategic investments in innovative companies. Malin seeks to partner with businesses across various life sciences sectors, including biotechnology, therapeutics, medical devices, and diagnostics. With a goal to support the development of breakthrough technologies, Malin engages in active collaboration and provides financial and strategic support to its investee companies. While continually expanding its portfolio, Malin maintains a strong commitment to driving advances in healthcare and delivering value to its shareholders.

Malin Corporation PLC has achieved several significant milestones. Firstly, the company successfully completed its initial public offering (IPO) on the Irish Stock Exchange in 2015, raising substantial funds for its investment portfolio. In 2016, Malin Corporation acquired a strategic stake in Poseida Therapeutics, an innovative gene engineering company. The company further expanded its portfolio by investing in promising life science companies like Immunocore, Kymab, and Serenus Biotherapeutics. In 2019, Malin Corporation celebrated the FDA approval of its investee company, Outpost Medicine's drug, for the treatment of overactive bladder. These achievements demonstrate Malin Corporation PLC's commitment to investing in breakthrough medical technologies and its potential for long-term growth.

Malin Corporation PLC primarily operates in Ireland.

Malin Corporation PLC represents a strong set of values and a well-defined corporate philosophy. The company is dedicated to delivering long-term shareholder value through strategic investments in innovative life sciences companies. Malin Corporation aims to support diverse and forward-thinking businesses that have the potential to positively impact global health. By fostering growth and nurturing breakthrough technologies, Malin Corporation PLC promotes collaboration and excellence within the life sciences industry. With a steadfast commitment to ethical practices and responsible investments, Malin Corporation PLC strives to enhance patient outcomes and contribute to the advancement of healthcare worldwide.

Analysts currently set an average price target of 15.81 EUR for the Malin Corporation stock (median: 15.81 EUR), implying +125.9 % versus the latest price. The consensus is based on 5 analyst ratings.

5 analysts currently rate the Malin Corporation stock: 4 recommend buying, 1 holding and 0 selling.

Malin Corporation PLC is an innovative Irish company specializing in investing in medical products. The company operates in various business areas, including the development and manufacture of pharmaceutical products, investment in innovative biotechnology startups, and the establishment of partnerships for scientific research projects. The manufacture of medical products is Malin's main business area. The company offers a wide range of products, ranging from drugs for rare diseases to antibiotics. The products are manufactured to the highest quality standards and are available to patients worldwide. An important part of Malin's business model is investing in innovative biotechnology startups. The company strives to find and support new technologies that contribute to improving human health. By collaborating with other companies and investors in the biotechnology field, Malin can advance innovative research and development that is of great benefit to its customers. Malin has also established partnerships for scientific research projects. Together with internationally leading research institutions and universities, the company is committed to the development of new drugs and therapies to meet the needs of patients. This collaboration aims to achieve scientific breakthroughs and find new treatment options for serious diseases. Overall, Malin's business model is focused on developing and providing innovative and effective drugs and therapies for patients. The company places special emphasis on adhering to high standards in research and production. By collaborating with other companies and research institutions, Malin achieves a broader base of knowledge, technology, and skills to remain competitive in the market. In summary, Malin Corporation PLC is an innovative company with a wide portfolio of medical products, investments in biotechnology startups, and research collaborations. With its focus on quality and innovation, Malin is a growing company that contributes to improving human health with its business model.

The revenue cannot currently be calculated for Malin Corporation.

The expected profit of Malin Corporation is -4.19 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Malin Corporation is currently -31.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Malin Corporation stock.

The P/S cannot be calculated for Malin Corporation currently.

The Eulerpool Quality Score for Malin Corporation is 1/10.

The ISIN of Malin Corporation is IE00BVGC3741. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Malin Corporation is MLC.IR. The ticker symbol is used to trade Malin Corporation shares on the stock exchange.

Malin Corporation paid dividends every year for the past 0 years.

Malin Corporation is assigned to the 'Health' sector.

The dividends of Malin Corporation are distributed in EUR.

Fair ValueTerminal
5.74 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website malinplc.com
Country
Ireland
Currency
EUR
Initial public offering
Mar 25, 2015
ISIN
IE00BVGC3741
Cusip
G5S5FH107
Sedol
BVGC374
Market capitalization
240.10 M EURMicro Cap
52-Week Range
6.80–8.65EUR
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2025
—
P/Ee 2026
-31.66
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
0.00 %
Gross Margin
24.88 %
EBIT Margin
null %
Net Margin
null %
EPS (Earnings Per Share)
0.00 EUR
Net Debt / EBIT
—
Debt/Equity
0.00
Last updated Sep 25, 2026, 4:20 AM

Malin Corporation Peer Group

Malin Corporation FIGI

MLC:ID · BBG0087MPRD5MLCI:L3 · BBG008D4JBV0MLCI:B3 · BBG008D4JCG5MLC1EUR:EO · BBG008D4JDB8MLC1EUR:XH · BBG008D4JDF4MLC1EUR:XF · BBG008D4JDH2MLC1EUR:XE · BBG008D4JDK8MLC1EUR:XJ · BBG008D4JDL7MLC1EUR:XL · BBG008D4JDM6MLC1EUR:XG · BBG008D4JDN5MLC1EUR:XO · BBG008D4JDP3MLC1EUR:XS · BBG008D4JDT9